<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) has been implicated as a potential causative factor for endogenous p53 mutations in gastrointestinal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the role of NO in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EADC), we studied patterns of p53 mutations, expression of inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS) and the tissue accumulation of nitrotyrosine (NTS), a stable reaction product of NO and a marker for cellular protein damage, in human premalignant and malignant esophageal epithelia </plain></SENT>
<SENT sid="2" pm="."><plain>Tissues were obtained from patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>)-induced <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (n = 76), <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE; n = 119) and primary EADC (n = 54) </plain></SENT>
<SENT sid="3" pm="."><plain>DNA sequencing was used to characterize p53 mutations, RT-PCR to study iNOS <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, and immunohistochemistry to study NTS </plain></SENT>
<SENT sid="4" pm="."><plain>Relative to self-matched <z:mpath ids='MPATH_458'>normal</z:mpath> epithelia, a progressive increase in iNOS <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> (30%; 23/76), BE (48%; 57/119), and EADC (63%; 34/54) tissues (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Among patients with EADC, elevated levels of NTS immunoreactivity were more frequent in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with p53 mutations (11/21; 52%) compared with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with <z:mp ids='MP_0002169'>wild-type</z:mp> p53 (9/33; 27%; P = 0.063), and specifically in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with p53 mutations at CpG <z:chebi fb="0" ids="47885">dinucleotides</z:chebi> (10/12; 83%) compared with non-CpG p53 mutations (1/9; 11%; P = 0.008) </plain></SENT>
<SENT sid="6" pm="."><plain>The increasing frequency of iNOS (<z:chebi fb="2" ids="33699">mRNA</z:chebi>) overexpression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, BE and EADC supports the hypothesis that an active inflammatory process, most likely a consequence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, underlies molecular progression to EADC </plain></SENT>
<SENT sid="7" pm="."><plain>The highly significant association between NTS, reflecting <z:hpo ids='HP_0011010'>chronic</z:hpo> NO-induced cellular protein damage, and endogenous p53 mutations at CpG <z:chebi fb="0" ids="47885">dinucleotides</z:chebi>, provides further evidence for a molecular link between <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> and esophageal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
</text></document>